

## Active substances set

**Search phrase:** Malignant pancreatic cancer

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

### Malignant pancreatic cancer

**Irinotecan  
hydrochloride  
trihydrate**

Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy



**NO REIMBURSEMENT**



**ESMO**

**Nab-paclitaxel**

Nab-Paclitaxel in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.



**REIMBURSEMENT  
WITH RESTRICTIONS**



**ESMO**